Department of Surgery and Radiology, Sections of Vascular Surgery and Interventional Radiology, Yale University School of Medicine, New Haven, Conn 06510, USA.
J Vasc Surg. 2010 Apr;51(4):1026-32, 1032.e1-1032.e2. doi: 10.1016/j.jvs.2009.10.103.
Ruptured descending thoracic aortic aneurysm (rDTAA) is associated with high mortality rates. Data supporting endovascular thoracic aortic aneurysm repair (TEVAR) to reduce mortality compared with open repair are limited to small series. We investigated published reports for contemporary outcomes of open and endovascular repair of rDTAA.
We systematically reviewed all studies describing the outcomes of rDTAA treated with open repair or TEVAR since 1995 using MEDLINE, Cochrane Library CENTRAL, and Excerpta Medica Database (EMBASE) databases. Case reports or studies published before 1995 were excluded. All articles were critically appraised for relevance, validity, and availability of data regarding treatment outcomes. All data were systematically pooled, and meta-analyses were performed to investigate 30-day mortality, myocardial infarction, stroke, and paraplegia rates after both types of repair.
Original data of 224 patients (70% male) with rDTAA were identified: 143 (64%) were treated with TEVAR and 81 (36%) with open repair. Mean age was 70 +/- 5.6 years. The 30-day mortality was 19% for patients treated with TEVAR for rDTAA compared 33% for patients treated with open repair, which was significant (odds ratio [OR], 2.15, P = .016). The 30-day occurrence rates of myocardial infarction (11.1% vs 3.5%; OR, 3.70, P < .05), stroke (10.2% vs 4.1%; OR, 2.67; P = .117), and paraplegia (5.5% vs 3.1%; OR, 1.83; P = .405) were increased after open repair vs TEVAR, but this failed to reach statistical significance for stroke and paraplegia. Five additional patients in the TEVAR group died of aneurysm-related causes after 30 days, during a median follow-up of 17 +/- 10 months. Follow-up data after open repair were insufficient. The estimated aneurysm-related survival at 3 years after TEVAR was 70.6%.
Endovascular repair of rDTAA is associated with a significantly lower 30-day mortality rate compared with open surgical repair. TEVAR was associated with a considerable number of aneurysm-related deaths during follow-up.
破裂的降主动脉胸主动脉瘤(rDTAA)与高死亡率相关。支持血管内胸主动脉瘤修复(TEVAR)降低死亡率的数据仅限于小系列。我们调查了公开报道的 rDTAA 的开放和血管内修复的当代结果。
我们使用 MEDLINE、Cochrane 图书馆 CENTRAL 和 Excerpta Medica Database(EMBASE)数据库系统地回顾了自 1995 年以来描述 rDTAA 用开放修复或 TEVAR 治疗的所有研究。排除 1995 年前发表的病例报告或研究。对所有文章的相关性、有效性和治疗结果数据的可用性进行了批判性评估。对所有数据进行了系统汇总,并进行荟萃分析,以研究两种类型修复后的 30 天死亡率、心肌梗死、卒中和截瘫率。
确定了 224 例 rDTAA 患者的原始数据(70%为男性):143 例(64%)接受 TEVAR 治疗,81 例(36%)接受开放修复。平均年龄为 70±5.6 岁。rDTAA 接受 TEVAR 治疗的患者 30 天死亡率为 19%,而接受开放修复的患者为 33%,差异有统计学意义(比值比[OR],2.15,P=0.016)。30 天心肌梗死(11.1%比 3.5%;OR,3.70,P<.05)、卒中和(10.2%比 4.1%;OR,2.67;P=0.117)和截瘫(5.5%比 3.1%;OR,1.83;P=0.405)的发生率在开放修复后升高,但卒中和截瘫的发生率无统计学意义。TEVAR 组另外 5 例患者在 30 天后死于与动脉瘤相关的原因,中位随访 17±10 个月。开放修复后随访数据不足。TEVAR 后 3 年的估计与动脉瘤相关的生存率为 70.6%。
与开放手术修复相比,rDTAA 的血管内修复与 30 天死亡率显著降低相关。TEVAR 在随访期间与相当数量的与动脉瘤相关的死亡有关。